

Catherine R Rowan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3546428/publications.pdf>

Version: 2024-02-01

9
papers

250
citations

1307594

7
h-index

1474206

9
g-index

9
all docs

9
docs citations

9
times ranked

454
citing authors

#	ARTICLE	IF	CITATIONS
1	Acceptance and Commitment Therapy Reduces Psychological Stress in Patients With Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2019, 156, 935-945.e1.	1.3	114
2	Ustekinumab Drug Levels in Maternal and Cord Blood in a Woman With Crohn's Disease Treated Until 33 Weeks of Gestation. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 376-378.	1.3	50
3	Visceral adiposity and inflammatory bowel disease. <i>International Journal of Colorectal Disease</i> , 2021, 36, 2305-2319.	2.2	24
4	Mucosal inflammation downregulates PHD1 expression promoting a barrier-protective HIF1 α response in ulcerative colitis patients. <i>FASEB Journal</i> , 2020, 34, 3732-3742.	0.5	16
5	Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 333-339.	3.7	14
6	Severe Symptomatic Primary CMV Infection in Inflammatory Bowel Disease Patients with Low Population Seroprevalence. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-5.	1.5	12
7	Hypoxia-inducible factor hydroxylase inhibition enhances the protective effects of cyclosporine in colitis. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, G90-G97.	3.4	10
8	Multifocal Motor Neuropathy Associated with Infliximab. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1174-1175.	1.3	7
9	An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 893-904.	1.8	3